CD133, OCT4, and NANOG in ulcerative colitis-associated colorectal cancer

Yasuda, Hiromi; Tanaka, Koji; Okita, Yoshiki; Araki, Toshimitsu; Saigusa, Susumu; Toiyama, Yuji; Yokoe, Takeshi; Yoshiyama, Shigeyuki; Kawamoto, Aya; Inoue, Yasuhiro; Miki, Chikao; Kusunoki, Masato

doi:10.3892/ol.2011.415

Cited by 27 publications

(21 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This was in line with previous investigations supporting the joint role of both biomarkers in controlling multiple pathways to govern the self-renewal characteristics and pluripotency of ESCs (60) and their positive involvement in tumor invasion and progression of many types of cancer (42,50,(61)(62)(63)(64). However, the functional impacts of both markers' coexpression in HCC need to be further explored, especially in our case, as a high level of NANOG expression was significantly associated with late-stage versus early-stage HCC compared to OCT3/4.…”

Section: Discussionsupporting

confidence: 77%

Stemness-Related Transcriptional Factors and Homing Gene Expression Profiles in Hepatic Differentiation and Cancer

Toraih

Fawzy

El-Falouji

et al. 2016

Mol Med

View full text Add to dashboard Cite

and 6 Pulmonologist, Ministry of Health, EgyptStem cell transcriptional signature activation is an essential event in the development of cancer. This study aimed to investigate the differential expression profiles of three pluripotency-associated genes, OCT4, NANOG and SOX2, G-protein-coupled chemokine receptor 4 (CXCR4) and the ligand CXCL2, and alpha-fetoprotein (AFP) in hepatogenic differentiated stem cells and in sera of hepatitis C virus (HCV) and HCV-induced hepatocellular carcinoma (HCC) patients. Mesenchymal stem cells derived from umbilical cord blood were differentiated using hepatogenic differentiation media. Serum specimens were collected from 96 patients (32 cirrhotic HCV, 32 early HCC and 32 late HCC) and 96 controls. Real-time quantitative reverse transcription polymerase chain reaction (qRT-PCR) was performed for relative quantification of the six target genes using the Livak method. In silico network analysis was also executed to explore the pluripotency and tumorigenetic regulatory circuits in liver cancer. The expression levels of all genes declined gradually during the stages of stem cell differentiation. On univariate and multivariate analyses, NANOG, CXCR4 and AFP were significantly upregulated in late clinical stage HCC patients. In contrast, SOX2 and CXCL2 were markedly overexpressed in cirrhotic patients and could be used for clear demarcation between cirrhotic and HCC patients in our cases. In conclusion, our data highlight the potential role of the SOX2 stem cell marker and CXCL2 chemokine in liver cell degeneration and fibrogenesis in HCV-induced hepatic cirrhosis in our sample of the Egyptian population. In addition, the significant association of NANOG and CXCR4 high expression with late HCC could contribute to the acquisition of stem celllike properties in hepatic cancer and dissemination in late stages, respectively. Taken together, our results could have potential application in HCC prognosis and treatment.

show abstract

Section: Discussionsupporting

confidence: 77%

Stemness-Related Transcriptional Factors and Homing Gene Expression Profiles in Hepatic Differentiation and Cancer

Toraih

Fawzy

El-Falouji

et al. 2016

Mol Med

View full text Add to dashboard Cite

show abstract

“…However, to the best of our knowledge, only one report has investigated the behavior and distribution of CD133 expression in UC-CRC and dysplasia, and the role of CD133 in the inflammation-dysplasia-carcinoma sequence has not been fully investigated. Specifically, Yasuda et al investigated CD133 expression in UC-CRC and inflamed colonic epithelium using real-time reverse-transcription polymerase chain reaction, and demonstrated that the level of CD133 expression in inflamed colonic epithelium was significantly lower in patients with UC with a longer duration of disease than in those with a shorter duration (19). They also examined CD133 expression in a small number (n=6) of UC-CRC cases.…”

Section: Discussionmentioning

confidence: 99%

Immunohistochemical Expression of CD133 and LGR5 in Ulcerative Colitis-associated Colorectal Cancer and Dysplasia

Kazama

Kishikawa

Tanaka

et al. 2019

In Vivo

View full text Add to dashboard Cite

Background/Aim: Cluster of differentiation 133 (CD133) and leu cine-rich orphan G-protein-coupled receptor 5 (LGR5) are the most putative stem cell markers for colorectal cancer (CRC), and are associated with poor prognosis of patients with CRC. However, the role of CD133 and LGR5 in the inflammation-dysplasia-carcinoma sequence has not been fully elucidated. We examined the expression of CD133 and LGR5 in ulcerative colitisassociated CRC (UC-CRC; n=20) and UC-associated colorectal dysplasia (n=16) by immunohistochemistry. Results: The rate of CD133-positive cases in UC-CRC was significantly higher than that in dysplasia (p=0.026), but that of LGR5 expression was not. Moreover, LGR5 expression was significantly positively associated with p53 expression (p=0.03), whereas CD133 expression positively correlated with p53 expression, but not significantly (p=0.10). Conclusion: CD133 may play an important role in tumor development in the context of the inflammationdysplasia-carcinoma sequence. LGR5-positive cancer stem cells may play a critical role in the development of UC-CRC, particularly upon loss of p53 function.

show abstract

“…Oct4 expression was significantly increased in GC tissues and its overexpression was found to be correlated with poor clinical prognosis . Overexpression of Oct‐4 has also been observed in sporadic colorectal cancer than those in adjacent normal colonic epithelium . Wen et al.…”

Section: Discussionmentioning

confidence: 99%

“…[8][9][10][11] Oct-4 has been revealed that it associated with the development, transformation, and metastasis of the tumours. 12 In addition, in a study by Yasuda et al, 13 have reported the high expression of Oct-4 on sporadic colorectal cancer. Moreover, another study by Wen et al 14 indicated the upregulation of Oct-4 was upregulated in metaplastic pancreatic ducts compared with normal acini and pancreatic carcinoma.…”

Section: Introductionmentioning

confidence: 96%

See 1 more Smart Citation

Differential expression of two genes Oct‐4 and MUC5AC associates with poor outcome in patients with gastric cancer

Javanbakht

Akhavan-Moghadam

Talaei

et al. 2017

Clin Exp Pharma Physio

View full text Add to dashboard Cite

Gastric cancer (GC) is the most frequent leading cause of cancer-associated mortality worldwide that is linked to poor prognosis due to the lack of appropriate biomarkers. Our aim was to evaluate the MUC5AC and Oct-4 expression levels in GC and to assess their association with clinical factors. Immunohistochemical analysis (IHC) and qRT-PCR were performed in GC patients to examine the MUC5AC and Oct-4 expression levels. The mRNA level of MUC5AC was significantly decreased in tumour tissues compared with non-cancerous tissues (1.11 ± 0.69 vs 3.7 ± 0.71; P = .024). On the other hand, Oct-4 mRNA level was upregulated in tumour tissues as compared to normal tissues (2. 86 ± 0.78 vs 0.87 ± 0.54; P = .0015). Decreased expression of MUC5AC was detected in 27 patients (67.5%), while high to moderate expression levels were observed in 13 cases (32.5%), but in normal tissues the expression levels of MUC5AC were increased (P = .001). The decreased expression of MUC5AC was associated with aggressive tumour characteristics, such as TNM stage (P = .023), histologic type (P = .012) and lymph node metastasis (P = .001). High expression of Oct-4 was detected in 24 tumour tissues (60%), while 16 cases (40%) showed low expression level. Increased Oct-4 expression was correlated with clinicopathological characteristics such TNM stage (P = .002), histologic type (P = .008) and lymph node metastasis (P = .001). Our results showed that high Oct-4 expression and the reduction of MUC5AC expression may be involved in the progression and an unfavorable prognosis of GC.

show abstract

CD133, OCT4, and NANOG in ulcerative colitis-associated colorectal cancer

Cited by 27 publications

References 23 publications

Stemness-Related Transcriptional Factors and Homing Gene Expression Profiles in Hepatic Differentiation and Cancer

Stemness-Related Transcriptional Factors and Homing Gene Expression Profiles in Hepatic Differentiation and Cancer

Immunohistochemical Expression of CD133 and LGR5 in Ulcerative Colitis-associated Colorectal Cancer and Dysplasia

Differential expression of two genes Oct‐4 and MUC5AC associates with poor outcome in patients with gastric cancer

Contact Info

Product

Resources

About